Tevogen Bio™ Further Strengthens IP Portfolio with Additional Patents for Methods of Manufacturing Its Investigational SARS-CoV-2-Specific T Cell Therapies – QNT Press Release

[ad_1]

  • Patented technology allows manufacture of hundreds of therapeutic doses of killer T cells (cytotoxic CD8+ T lymphocytes) from a single donor

  • Tevogen’s investigational T-cell therapy TVGN-489 is designed to detect targets spread across the entire viral genome, not just the spike protein

Tevergan BioA clinical-stage biotechnology company focused on cell and gene therapy for oncology and viral infections announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,219,684) for the preparation of COVID-19 peptide-specific cytotoxic T cells (CTLs) for the treatment of COVID-19 infection.Patent further strengthens biotech pioneer’s expanding intellectual property folder.

“The extensive mutation of Omicron and its subsequent ability to evade antibodies underscores the importance of killer T cells that can still recognize and eliminate virus-infected cells,” said Tevogen CEO Ryan Sadie, MD, MPH “Millions of us suffer from inadequate T cell responses for a variety of reasons. After two years of the pandemic and witnessing the challenges posed by an evolving virus, we must explore the scientific choose……

The full story is available on Benzinga.com

[ad_2]

Source link

Recommended For You

About the Author: News Center